These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21546862)

  • 1. PharmGKB summary: citalopram pharmacokinetics pathway.
    Sangkuhl K; Klein TE; Altman RB
    Pharmacogenet Genomics; 2011 Nov; 21(11):769-72. PubMed ID: 21546862
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding of S-citalopram and paroxetine discriminates between species.
    Elfving B; Wiborg O
    Synapse; 2005 Mar; 55(4):280-2. PubMed ID: 15668984
    [No Abstract]   [Full Text] [Related]  

  • 3. N-methyl-citalopram: A quaternary selective serotonin reuptake inhibitor.
    Bismuth-Evenzal Y; Roz N; Gurwitz D; Rehavi M
    Biochem Pharmacol; 2010 Nov; 80(10):1546-52. PubMed ID: 20696140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.
    Joffe P; Larsen FS; Pedersen V; Ring-Larsen H; Aaes-Jørgensen T; Sidhu J
    Eur J Clin Pharmacol; 1998 May; 54(3):237-42. PubMed ID: 9681666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and pharmacokinetics of citalopram and other SSRIs.
    Baumann P
    Int Clin Psychopharmacol; 1996 Mar; 11 Suppl 1():5-11. PubMed ID: 8732438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PharmGKB summary: venlafaxine pathway.
    Sangkuhl K; Stingl JC; Turpeinen M; Altman RB; Klein TE
    Pharmacogenet Genomics; 2014 Jan; 24(1):62-72. PubMed ID: 24128936
    [No Abstract]   [Full Text] [Related]  

  • 7. Interaction potential of selective serotonin-reuptake inhibitors.
    DeVane CL
    Am J Health Syst Pharm; 2000 Oct; 57(19):1802-3. PubMed ID: 11030037
    [No Abstract]   [Full Text] [Related]  

  • 8. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical interactions with antidepressives. Benefits of the specific serotonin reuptake inhibitor citalopram].
    Eckert A; Reiff J; Müller WE
    Med Monatsschr Pharm; 1998 May; 21(5):138-50. PubMed ID: 9617102
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure.
    Goutelle S; Tod M
    Clin Pharmacokinet; 2015 Mar; 54(3):319-20. PubMed ID: 25559340
    [No Abstract]   [Full Text] [Related]  

  • 11. Citalopram distribution in postmortem cases.
    Levine B; Zhang X; Smialek JE; Kunsman GW; Frontz ME
    J Anal Toxicol; 2001 Oct; 25(7):641-4. PubMed ID: 11599616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative methods for prediction of the effect of cytochrome P450 gene polymorphisms on substrate drug exposure: authors' reply.
    Lindh JD; Chang M; Tybring G; Dahl ML
    Clin Pharmacokinet; 2015 Mar; 54(3):321. PubMed ID: 25488593
    [No Abstract]   [Full Text] [Related]  

  • 13. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
    Owens MJ; Knight DL; Nemeroff CB
    Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.
    Rocha A; Coelho EB; Sampaio SA; Lanchote VL
    Br J Clin Pharmacol; 2010 Jul; 70(1):43-51. PubMed ID: 20642546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.
    Brøsen K; Naranjo CA
    Eur Neuropsychopharmacol; 2001 Aug; 11(4):275-83. PubMed ID: 11532381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
    Hicks JK; Bishop JR; Sangkuhl K; Müller DJ; Ji Y; Leckband SG; Leeder JS; Graham RL; Chiulli DL; LLerena A; Skaar TC; Scott SA; Stingl JC; Klein TE; Caudle KE; Gaedigk A;
    Clin Pharmacol Ther; 2015 Aug; 98(2):127-34. PubMed ID: 25974703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Citalopram pharmacokinetic interaction with clomipramine. UDP-glucuronosyltransferase inhibition? A case report.
    Haffen E; Vandel P; Bonin B; Vandel S
    Therapie; 1999; 54(6):768-70. PubMed ID: 10709456
    [No Abstract]   [Full Text] [Related]  

  • 18. Citalopram for depression.
    Med Lett Drugs Ther; 1998 Dec; 40(1041):113-4. PubMed ID: 9854566
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatotoxicity related to citalopram.
    López-Torres E; Lucena MI; Seoane J; Verge C; Andrade RJ
    Am J Psychiatry; 2004 May; 161(5):923-4. PubMed ID: 15121663
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.
    Preskorn SH
    Clin Pharmacokinet; 1997; 32 Suppl 1():1-21. PubMed ID: 9068931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.